Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS‑102 plus bevacizumab

Autor:	Sawako, Tamaki, Hideki, Ishikawa, Koichi, Suzuki, Yasuaki, Kimura, Ryo, Maemoto, Iku, Abe, Yuhei, Endo, Nao, Kakizawa, Fumiaki, Watanabe, Kazushige, Futsuhara, Masaaki, Saito, Shingo, Tsujinaka, Yasuyuki, Miyakura, Toshiki, Rikiyama
Rok vydání:	2022
Předmět:	Cancer Research Oncology
Zdroj:	Molecular and Clinical Oncology. 16
ISSN:	2049-9469 2049-9450
Popis:	Combined treatment with bevacizumab and trifluridine/tipiracil (TAS-102) leads to an increased chance of survival in patients with refractory metastatic colorectal cancer (mCRC); however, this treatment is associated with an increased frequency of severe neutropenia (number of neutrophils1,000), which should ideally be managed without dose delays. The present study provided a retrospective review of 35 patients with mCRC, and aimed to elucidate the benefits of prophylactic pegfilgrastim for the treatment of severe neutropenia. Patients received TAS-102 (35 mg/m
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044d8fa8c17a1e0069d4bd769200650f https://doi.org/10.3892/mco.2022.2536 Zobrazit plný text záznamu